Deals of the Week: GSK Working On Three Deals, Agilent/Dako
Executive Summary
GlaxoSmithKline tries to turn partnerships into acquisitions with varying results, as one company accepts a buy-out while another adopts a poison-pill strategy.
You may also be interested in...
India’s Piramal Buys Bayer’s Molecular Imaging Research Portfolio To Bulk Up Innovative Pipeline
Piramal steadily carving out a pipeline that will give it a niche in the global pharma business.
Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under Review
The surprise announcement by Merck Serono to return all rights to safinamide to Italy's Newron has led to Biotie Therapies and Newron reviewing their plans to merge.
GSK Taps Cellzome For Inflammatory Disease Deal
GSK will pay Cellzome £14.4 million upfront for options to Kinobeads drug candidates.